Overview
Portfolio
More
Genoa Ventures
Genoa Ventures invests in companies at the intersection of biology and technology, seeking category‑defying businesses that can create healthier, cleaner and more productive outcomes. They focus on early‑stage ventures t...
Portfolio
19+
Employees
N/A
Founded
N/A
AUM
≈ $108.0M
Investment focus
Stages
No stages listed
Industries
BiotechnologyHealthcare Technology
Geographic scope
United States
Fund details
Funds
Fund I
Vintage 2019 • $24.1
Fund II
Vintage 2022 • $84.0
Sources
Genoa Ventures
Genoa Ventures invests in companies at the intersection of biology and technology, seeking category‑defying businesses that can create healthier, cleaner and more productive outcomes. They focus on early‑stage ventures that combine deep scientific breakthroughs with scalable tech platforms to accelerate innovation across life sciences and related sectors.
Portfolio
19+
Employees
N/A
Founded
N/A
AUM
≈ $108.0M
Funds
Fund I · Vintage 2019 • $24.1
Fund II · Vintage 2022 • $84.0
Stages
No stages listed
Industries
BiotechnologyHealthcare Technology
Geographic scope
United States
Sources
Showing 17 of 17 matched portfolio companies
AlidaBio provides the EpiPlex platform, a proximity‑barcoding workflow that simultaneously detects m6A, inosine, and pseudouridine alongside whole‑transcriptome expression from low‑input or degraded RNA samples such as FFPE and liquid biopsies. The solution is offered as a turnkey service or in‑lab kits, with machine‑learning‑driven EpiScout software delivering normalized quantification, quality metrics, and visual reports in a single, seven‑hour workflow.
Funding: $7.5M
Rough estimate of the amount of funding raised
+ 1 Other investorGenoa Ventures
+ 1 Other investorGenoa Ventures
Funding: $7.5M
Rough estimate of the amount of funding raised
Aqtual, Inc. utilizes a proprietary cell-free DNA platform to develop highly accurate blood tests for chronic diseases and oncology, focusing on biomarkers that guide therapy management. The company addresses the challenge of ineffective treatment responses in chronic inflammatory conditions, such as rheumatoid arthritis, by providing clinically actionable insights from a single blood draw.
Funding: $31.9M
Rough estimate of the amount of funding raised
Manta Ray VenturesYu Galaxy
Manta Ray VenturesYu Galaxy
Funding: $31.9M
Rough estimate of the amount of funding raised
Attune Neurosciences develops a non-invasive medical device that utilizes low-intensity focused ultrasound to precisely target and modulate activity in the deep brain. This technology aims to improve treatment outcomes for chronic pain and various psychiatric and neurological conditions by addressing the limitations of current therapeutic options.
Funding: $3.8M
Rough estimate of the amount of funding raised
Funding: $3.8M
Rough estimate of the amount of funding raised
Bond Pet Foods utilizes biotechnology to produce nature-identical animal proteins through fermentation processes, eliminating the need for traditional livestock farming. This approach addresses the environmental impact of pet food production by providing sustainable, scalable protein sources that meet the nutritional needs of dogs and cats.
Funding: $20.0M
Rough estimate of the amount of funding raised
Funding: $20.0M
Rough estimate of the amount of funding raised
BRAINBox Solutions™ utilizes blood biomarker panels and tablet-based neurocognitive testing to provide objective evidence of mild traumatic brain injury (mTBI) and predict post-injury symptom outcomes. This multi-modality approach enhances diagnostic accuracy and informs clinicians about the likelihood of recovery, addressing the need for improved assessment in traumatic brain injury cases.
Funding: $23.0M
Rough estimate of the amount of funding raised
Genoa Ventures
Genoa Ventures
Funding: $23.0M
Rough estimate of the amount of funding raised
BrightSpec offers the spectraMRR™ platform, which uses Molecular Rotational Resonance (MRR) spectroscopy to directly identify and quantify small‑molecule structures from liquids, gases, or headspace without chromatography, derivatization, or extensive sample preparation. The system combines ultra‑high‑resolution rotational fingerprinting with quantum‑simulation software and SpectrAline™ sample‑introduction cartridges to deliver rapid, automated, and highly accurate analysis for pharmaceutical, chemical, food safety, and consumer‑goods applications.
Funding: $18.4M
Rough estimate of the amount of funding raised
+ 3 Other investorsArboretum VenturesGenoa Ventures
+ 3 Other investorsArboretum VenturesGenoa Ventures
Funding: $18.4M
Rough estimate of the amount of funding raised
Codetta Bio develops a digital spatial platform that integrates digital PCR and qPCR technologies for the multiplex measurement of blood-based protein biomarkers. This platform reduces analysis time from two days to two hours, enhancing the sensitivity and efficiency of multi-omics assays in translational research and clinical applications.
Funding: $27.3M
Rough estimate of the amount of funding raised
Funding: $27.3M
Rough estimate of the amount of funding raised
Epitel provides the REMI Remote EEG Monitoring System for accurate, high-fidelity electroencephalogram recordings in healthcare and ambulatory settings. This wireless system utilizes minimal sensors for patient comfort and allows for rapid setup and near real-time data transmission to established EEG monitoring platforms. The offering includes REMI Vigilenz AI for automated event detection to assist qualified physicians in reviewing potential electrographic seizure activity.
Funding: $12.5M
Rough estimate of the amount of funding raised
Catalyst Health VenturesGenoa Ventures
Catalyst Health VenturesGenoa Ventures
Funding: $12.5M
Rough estimate of the amount of funding raised
The startup offers a male fertility analysis kit that provides lab-grade results through a physician-approved process. Users send a sample to the company's lab for analysis, gaining insights into their fertility health without the need for a clinical visit.
Funding: $29.5M
Rough estimate of the amount of funding raised
Funding: $29.5M
Rough estimate of the amount of funding raised
InterVenn Biosciences utilizes its GlycoVision™ platform to conduct high-resolution glycoproteomic analysis, enabling the discovery of biomarkers for disease detection and therapeutic response. By examining protein glycosylation, the company provides critical insights into the molecular mechanisms of health and disease, facilitating personalized and preventive healthcare solutions.
Funding: $244.1M
Rough estimate of the amount of funding raised
SoftBank Capital
SoftBank Capital
Funding: $244.1M
Rough estimate of the amount of funding raised
Meiogenix provides a proprietary targeted recombination platform that directs natural chromosome exchanges to unlock hidden genetic diversity in crops, enabling faster development of elite, climate‑resilient varieties without foreign DNA. By licensing this technology to seed companies and breeding programs, it shortens breeding cycles from over a decade to a few years while allowing precise trait introgression, linkage drag removal, and complex trait stacking across major and specialty crops.
+ 1 Other investorAlexandria Venture Investments
Hermes Biosciences offers a benchtop, hands-off system for the rapid and reproducible isolation of exosomes directly from bodily fluids and cell culture media. This technology enables researchers to efficiently purify extracellular vesicles for functional studies. The system supports advancements in clinical applications across oncology, degenerative disease, and regenerative medicine.
20+
2K+Approximate amount of employees
New Culture utilizes traditional cheesemaking techniques combined with modern fermentation technology to produce animal-free mozzarella that mimics the taste and texture of conventional cheese. This process eliminates lactose, cholesterol, hormones, and antibiotics while significantly reducing resource consumption, making it a sustainable alternative in the dairy industry.
Funding: $30.2M
Rough estimate of the amount of funding raised
CJ CheilJedang Corp.
CJ CheilJedang Corp.
Funding: $30.2M
Rough estimate of the amount of funding raised
Redux Bio develops RNA interference (RNAi) products that silence essential genes in bacterial, viral, and parasitic pathogens, providing a non‑antibiotic, species‑specific disease‑prevention solution for livestock and aquaculture. The formulations are designed for oral delivery through feed or water, allowing seamless integration into existing husbandry practices while reducing disease incidence and antimicrobial resistance.
5+
100+Approximate amount of employees
The startup develops a medical platform that utilizes computational oncology to create personalized virtual tumors from diagnostic datasets, enhancing the understanding of cancer for healthcare providers. This approach enables more tailored treatment plans, improving patient outcomes in cancer care.
Funding: $21.2M
Rough estimate of the amount of funding raised
Genoa VenturesNorthpond Ventures
Genoa VenturesNorthpond Ventures
Funding: $21.2M
Rough estimate of the amount of funding raised
Tropic Biosciences develops high-performing tropical crop varieties using CRISPR gene editing and RNA interference to enhance disease resistance and reduce pesticide reliance. Their technology addresses the challenges of climate change and food security by improving the yield and resilience of staple crops like bananas, coffee, and rice.
Funding: $75.4M
Rough estimate of the amount of funding raised
Funding: $75.4M
Rough estimate of the amount of funding raised
ZwitterCo develops zwitterionic membranes that effectively filter fats, oils, and proteins from highly impaired wastewater, enabling reliable water treatment in challenging environments. Their technology significantly reduces cleaning frequency and costs, allowing for up to 95% water reuse in industrial applications.
Showing 2 of 2 unmatched portfolio companies